Use of inhibitors of Bruton's tyrosine kinase (Btk)
US10016435B2 · kind B2 · utility
11Cited by
141References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 2017 |
| Grant date | Jul 10, 2018 |
| Priority date | — |
| Expiry date | Sep 26, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.